Parabilis holder reports Series F convertible stake
Parabilis Medicines, Inc. filed an initial ownership report showing that investment entities associated with Soleus Capital hold Series F Preferred Stock that is convertible into 527,070 shares of Common Stock at a conversion price of $9.48 per share.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Parabilis Medicines, Inc. filed an initial ownership report showing that investment entities associated with Soleus Capital hold Series F Preferred Stock that is convertible into 527,070 shares of Common Stock at a conversion price of $9.48 per share. The securities are owned directly by Soleus Private Equity Fund III, L.P., with various Soleus general partner and management entities, and Guy Levy, identified as indirect 10% owners. The filing notes that the preferred stock is convertible at any time at the holder’s election and has no expiration date, and the reporting persons disclaim beneficial ownership beyond their pecuniary interests.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Levy Guy, Soleus Private Equity Fund III, L.P., Soleus Private Equity GP III, LLC, Soleus PE GP III, LLC, Soleus Capital Management, L.P., Soleus GP, LLC
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Series F Preferred Stock | -- | -- | -- |
Holdings:
Series F Preferred Stock — 527,070 contracts (Indirect, See footnote)
Footnotes (2)
- F1. The reportable securities are owned directly by Soleus Private Equity Fund III, L.P. ("Soleus PE"). Soleus Private Equity GP III, LLC ("Soleus PE GP") is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. ("SCM") is the investment manager for Soleus PE, and Soleus GP, LLC ("Soleus GP") is the sole general partner of SCM. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and Soleus GP. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, SCM and Soleus GP disclaims beneficial ownership of the securities held by Soleus PE other than for the purpose of determining their obligations under Section 16 of the Securities Exchange Act of 1934, as amended, and the filing of this report shall not be deemed an admission that any of the foregoing persons is the beneficial owner of such securities for any other purpose, except to the extent of their respective pecuniary interests therein.
- F2. The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.
Key Figures
Underlying common shares: 527,070 shares
Conversion price: $9.48 per share
2 metrics
Underlying common shares
527,070 shares
Underlying Common Stock for Series F Preferred Stock holdings
Conversion price
$9.48 per share
Conversion price of Series F Preferred Stock into Common Stock
Key Terms
Series F Preferred Stock, convertible preferred stock, beneficial ownership, Section 16 of the Securities Exchange Act of 1934
4 terms
Series F Preferred Stock financial
"The reportable securities are owned directly by Soleus Private Equity Fund III, L.P."
Series F preferred stock is a class of company shares that gives holders priority over common shareholders for dividend payments and for getting money back if the company is sold or liquidated, much like a ticket that moves you to the front of the line. These shares often carry a fixed dividend and special rights—sometimes including conversion into common stock—so investors consider them when weighing income, downside protection and potential ownership dilution.
convertible preferred stock financial
"The convertible preferred stock is convertible at any time, at the holder's election"
Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.
beneficial ownership financial
"disclaims beneficial ownership of the securities held by Soleus PE"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 of the Securities Exchange Act of 1934 regulatory
"for the purpose of determining their obligations under Section 16 of the Securities Exchange Act of 1934"
A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Parabilis Medicines (PBLS) Form 3 filing disclose?
The Form 3 discloses initial ownership of convertible preferred stock. Entities associated with Soleus Capital report holdings of Series F Preferred Stock in Parabilis Medicines, convertible into 527,070 common shares at $9.48 per share, establishing them as significant, over-10% beneficial owners.
Who actually owns the Parabilis Medicines (PBLS) securities reported in this Form 3?
The securities are owned directly by Soleus Private Equity Fund III, L.P. Related Soleus entities and Guy Levy are listed as indirect 10% owners. The filing explains that these parties disclaim beneficial ownership except to the extent of their respective pecuniary interests.
What are the conversion terms of the Parabilis Medicines (PBLS) Series F Preferred Stock?
The convertible preferred stock can be converted at any time by the holder. The filing notes that the Series F Preferred Stock has no expiration date and is convertible into Common Stock at a conversion price of $9.48 per share, at the holder’s election.
Why is Guy Levy listed on the Parabilis Medicines (PBLS) Form 3?
Guy Levy is identified as the managing member of key Soleus entities. The filing explains his control roles in Soleus general partner and management entities but states he disclaims beneficial ownership of Soleus PE’s securities, except for his pecuniary interest under Section 16 rules.
Does the Parabilis Medicines (PBLS) Form 3 show any recent buy or sell transactions?
The Form 3 functions as an initial ownership statement, not a trade report. It presents holdings of Series F Preferred Stock and the related 527,070 underlying common shares, rather than documenting new purchases or sales of Parabilis Medicines securities.
AI-generated analysis. How Rhea-AI works. Not financial advice.
